
Switchpoint Bio
Developer of a blood-based epigenomic platform providing drug developers with insights into disease and treatment response.
About
Switchpoint Bio develops a blood-based epigenomic platform that profiles epigenomic marks from circulating immune cells to give drug developers a scalable view of how disease and treatment change human biology. By combining precision epigenomic profiling with AI, the platform enables biomarker discovery, patient stratification and treatment response monitoring for pharmaceutical R&D.
Key facts
- Website
- switchpointbio.com
- Headquarters
- Helsinki, Finland
- Founded
- 2025
- Employees
- 8
- Total funding
- $5M (Pre-Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Nov 2026 | Pre-Seed | $5M |
Tech stack
Detected on switchpointbio.com, last scanned 12 Nov 2026. Run your own scan
- CMS / Builders
- Squarespace
- Email provider
- Google Workspace
- Hiring platform
- Teamtailor
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Switchpoint Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Switchpoint Bio is 72 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Switchpoint Bio raised?
Switchpoint Bio has raised a total of $5M in funding. The most recent round on record is Pre-Seed.
How many employees does Switchpoint Bio have?
Switchpoint Bio has approximately 8 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Switchpoint Bio:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules


